Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | PO / MO |
The patient took one dose on 22-Mar-2025; Case reference number US-BN-2025-000404 is a spontaneous case report initially received from a pharmacist via agency (reference number: USBAV25-0675) on 25-Mar-2025 and concerns a female patient of unspecified age. The patient's relevant medical history and concomitant medications were not provided. On 22-Mar-2025, the patient took first dose of Vivotif vaccine (batch number: unknown) the dose was unknown, orally for indication repoted as pre-travel. (explicitly coded as 'inappropriate schedule of vaccine administered'). As reported, the patient left it out at ambient temperatures for days and will not be able to take those remaining capsules. At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. No further information was provided.; Reporter's Comments: A female patient of unspecified age, took the first dose of Vivotif vaccine on 22-Mar-2025 for indication reported as pre-travel, and the patient was not able to take the remaining capsules, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age, took the first dose of Vivotif vaccine on 22-Mar-2025 for indication reported as pre-travel, and the patient was not able to take the remaining capsules, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.